MML Investors Services LLC Increases Stock Holdings in Fresenius Medical Care AG (NYSE:FMS)

MML Investors Services LLC increased its holdings in Fresenius Medical Care AG (NYSE:FMS) by 5.3% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 15,019 shares of the company’s stock after buying an additional 753 shares during the period. MML Investors Services LLC’s holdings in Fresenius Medical Care were worth $320,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in the business. Creative Planning raised its position in Fresenius Medical Care by 18.9% during the second quarter. Creative Planning now owns 40,140 shares of the company’s stock worth $766,000 after acquiring an additional 6,373 shares during the last quarter. Verition Fund Management LLC acquired a new position in shares of Fresenius Medical Care during the 3rd quarter worth approximately $237,000. Wulff Hansen & CO. lifted its stake in Fresenius Medical Care by 1,809.0% in the 2nd quarter. Wulff Hansen & CO. now owns 343,429 shares of the company’s stock valued at $6,556,000 after buying an additional 325,439 shares in the last quarter. Quantinno Capital Management LP grew its holdings in Fresenius Medical Care by 78.9% during the 3rd quarter. Quantinno Capital Management LP now owns 110,078 shares of the company’s stock valued at $2,345,000 after buying an additional 48,554 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in Fresenius Medical Care by 11.2% during the third quarter. Charles Schwab Investment Management Inc. now owns 22,161 shares of the company’s stock worth $472,000 after buying an additional 2,233 shares in the last quarter. 8.37% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

FMS has been the topic of several recent research reports. StockNews.com began coverage on Fresenius Medical Care in a research report on Thursday, November 28th. They issued a “strong-buy” rating on the stock. Berenberg Bank began coverage on shares of Fresenius Medical Care in a report on Wednesday, November 6th. They issued a “buy” rating and a $25.60 target price on the stock. Truist Financial lifted their price target on shares of Fresenius Medical Care from $22.00 to $23.00 and gave the stock a “hold” rating in a report on Monday, October 7th. Finally, Bank of America raised shares of Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a research note on Monday, December 2nd. One analyst has rated the stock with a sell rating, two have given a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $24.30.

Fresenius Medical Care Stock Up 0.1 %

Shares of NYSE:FMS opened at $22.71 on Wednesday. The company has a current ratio of 1.37, a quick ratio of 1.02 and a debt-to-equity ratio of 0.42. The firm has a market cap of $13.33 billion, a price-to-earnings ratio of 18.77, a PEG ratio of 0.96 and a beta of 0.93. The stock’s 50-day moving average price is $21.88 and its two-hundred day moving average price is $20.54. Fresenius Medical Care AG has a 12-month low of $17.93 and a 12-month high of $24.31.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.